Global Flu Vaccine Market Research Report 2026(Status and Outlook)

May 2026 | 139 pages | ID: G246A1341D30EN
Bosson Research

Abstracts

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Flu Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.Flu Vaccine refers to a preventive biological product that uses seasonal or potentially pandemic strains as antigens to reduce influenza-related morbidity and complications through human immunization strategies. Its technological pathways encompass inactivated and live-attenuated platforms and can switch among different manufacturing systems (egg-based, cell-culture, recombinant protein, etc.) to address antigenic drift and annual strain updates. On the regulatory side, a seasonal “recommendation–update–release” cadence has been institutionalized (as reflected in WHO position papers and national immunization guidelines), alongside a consistent framework for dosage forms, routes of administration, and eligible populations (e.g., programmatic annual vaccination for individuals ?6 months of age). Within this framework, the vaccine functions both as a public-health intervention and as a vehicle for global supply-chain coordination and regulatory-science iteration, embodying end-to-end alignment “from strain selection, process engineering, and quality control to vaccination scenarios.”Market Opportunities & Drivers: How can the convergence of “annual immunization + technology evolution + policy support” reshape value?The steady reinforcement of annual immunization strategies creates a predictable clinical setting for vaccination (e.g., ACIP’s routine annual recommendation for individuals ?6 months), while the EU’s seasonal strain recommendations and pandemic fast-track pathways together establish a clear “policy–manufacture–release” supply continuum. On the technology side, cell-based and recombinant protein platforms improve adaptability to rapidly evolving strains; differentiated options such as high-dose/adjuvanted inactivated vaccines and intranasal live-attenuated formulations further segment value across populations. In the United States, authorization for intranasal vaccines to be administered at home by patients/caregivers broadens reach and adherence. Leading manufacturers are simultaneously investing in capacity and modernized processes (e.g., new high-dose Flu Vaccine units in France) to add resilience against demand swings across pandemic and seasonal scenarios. Challenges persist around strain-match uncertainty, coordination across dual seasons in different hemispheres, and ongoing commitments to cold-chain and compliance. Industry/Supply Chain: How does the closed loop from “antigen—manufacturing line—vaccination setting” to “brand—channel—service” take shape? Upstream relies on seed stocks, controlled substrates (eggs/cell lines), and excipient systems under modular quality and clinical standards. Midstream facilities with multi-platform capabilities support rapid seasonal strain switches and intra-year dual-season rotations across intercontinental networks in Europe, North America, and Australia. Representative companies include Sanofi (recombinant/high-dose portfolio), CSL Seqirus (cell-based and adjuvanted combinations with sites across the US/EU/Australia), GSK (Fluarix/FluLaval), AstraZeneca (FluMist/Fluenz intranasal LAIV), as well as active producers in China and Japan such as Hualan Bio, Changchun Institute of Biological Products (WHO-PQ), Sinovac, BCHT (intranasal LAIV), Jiangsu GDK, and KM Biologics (Japan, HA-split). Downstream, national immunization programs, pharmacies, and primary-care networks work in concert; in some markets, “home delivery and self-administration” is emerging, enriching access modes and real-world vaccination scenarios. Segmentation Trends: Which populations and settings are shaping differentiated product positions? Older adults and people with comorbidities increasingly prefer “immune-enhanced” approaches, making high-dose/adjuvanted inactivated vaccines a focal point in clinical dialogue. Pediatric and school settings value needle-free convenience and mucosal immunity; intranasal live-attenuated Flu Vaccines have accumulated long-term real-world evidence in certain markets and have expanded to home self-/caregiver administration. Markets sensitive to egg-based constraints—or seeking faster strain switches—show rising interest in cell-based and recombinant technologies. Public-health and emergency-preparedness bodies emphasize integrated readiness for both seasonal and potential pandemic use, advancing standby supply and rapid-switch mechanisms with manufacturers. Overall, a “population–platform–setting” triad is taking shape: multiple technologies coexist within the same market to meet diverse clinical needs. Regional Trends: How do North America, Europe, and Asia-Pacific each play to their strengths in strategy and supply? North America is characterized by strong alignment of guidelines and channels: CDC’s annual consensus is well established, and pharmacy networks plus home-administration options widen reach. Europe leverages EMA’s programmatic processes for seasonal composition and pandemic vaccines, emphasizing scientific consistency and rapid response. China and the broader Asia-Pacific accelerate “localized production + convergence with international norms”: some enterprises have obtained WHO-PQ and serve multiple markets, while Japanese manufacturers maintain in-country production with institutionalized annual strain updates, forming a stable regional supply. In sum, North America and Europe reinforce mature “standards–channels–compliance” linkages, while Asia-Pacific advances on “localized capacity—platform diversity—outbound supply.”Latest DevelopmentsApril 1, 2025: EMA issued Flu Vaccine composition recommendations for the 2025/2026 season, reaffirming the WHO-guided annual strain-update mechanism and providing a consistent basis for EU registrations and lot release?September 20, 2024: AstraZeneca announced that FluMist in the United States was approved for self-/caregiver administration at home, expanding access and convenience for intranasal live-attenuated vaccination?May 13, 2024: Sanofi announced capacity expansion in France for high-dose Flu Vaccines and related capabilities, strengthening Europe’s seasonal and emergency manufacturing resilience.

The global Flu Vaccine market size was estimated at USD 8955.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 5.50% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Flu Vaccine market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Flu Vaccine market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Flu Vaccine market.

Global Flu Vaccine Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

• Sanofi
• CSL
• GSK
• AstraZeneca
• Hualan Bio
• Changchun Institute of Biological
• Sinovac
• BCHT
• Jiangsu GDK
• KM Biologics

Market Segmentation (by Type)

• Trivalent Influenza Vaccine
• Quadrivalent Influenza Vaccine

Market Segmentation (by Application)

• 6 Months to 3 Years
• > 3 Years

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Flu Vaccine Market

Overview of the regional outlook of the Flu Vaccine Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Flu Vaccine Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Flu Vaccine, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Flu Vaccine
1.2 Key Market Segments
  1.2.1 Flu Vaccine Segment by Type
  1.2.2 Flu Vaccine Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 FLU VACCINE MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Flu Vaccine Market Size (M USD) Estimates and Forecasts (2020-2035)
  2.1.2 Global Flu Vaccine Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 FLU VACCINE MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant
3.2 Global Flu Vaccine Product Life Cycle
3.3 Global Flu Vaccine Sales by Manufacturers (2020-2025)
3.4 Global Flu Vaccine Revenue Market Share by Manufacturers (2020-2025)
3.5 Flu Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Flu Vaccine Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Flu Vaccine Market Competitive Situation and Trends
  3.8.1 Flu Vaccine Market Concentration Rate
  3.8.2 Global 5 and 10 Largest Flu Vaccine Players Market Share by Revenue
  3.8.3 Mergers & Acquisitions, Expansion

4 FLU VACCINE INDUSTRY CHAIN ANALYSIS

4.1 Flu Vaccine Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF FLU VACCINE MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
  5.4.1 New Product Developments
  5.4.2 Mergers & Acquisitions
  5.4.3 Expansions
  5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
  5.5.1 Industry Policies Analysis
  5.5.2 Economic Environment Analysis
  5.5.3 Social Environment Analysis
  5.5.4 Technological Environment Analysis
5.6 Global Flu Vaccine Market Porter's Five Forces Analysis
  5.6.1 Global Trade Frictions
  5.6.2 U.S. Tariff Policy – April 2025
  5.6.3 Global Trade Frictions and Their Impacts to Flu Vaccine Market
5.7 ESG Ratings of Leading Companies

6 FLU VACCINE MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Flu Vaccine Sales Market Share by Type (2020-2025)
6.3 Global Flu Vaccine Market Size by Type (2020-2025)
6.4 Global Flu Vaccine Price by Type (2020-2025)

7 FLU VACCINE MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Flu Vaccine Market Sales by Application (2020-2025)
7.3 Global Flu Vaccine Market Size (M USD) by Application (2020-2025)
7.4 Global Flu Vaccine Sales Growth Rate by Application (2020-2025)

8 FLU VACCINE MARKET SALES BY REGION

8.1 Global Flu Vaccine Sales by Region
  8.1.1 Global Flu Vaccine Sales by Region
  8.1.2 Global Flu Vaccine Sales Market Share by Region
8.2 Global Flu Vaccine Market Size by Region
  8.2.1 Global Flu Vaccine Market Size by Region
  8.2.2 Global Flu Vaccine Market Size by Region
8.3 North America
  8.3.1 North America Flu Vaccine Sales by Country
  8.3.2 North America Flu Vaccine Market Size by Country
  8.3.3 U.S. Market Overview
  8.3.4 Canada Market Overview
  8.3.5 Mexico Market Overview
8.4 Europe
  8.4.1 Europe Flu Vaccine Sales by Country
  8.4.2 Europe Flu Vaccine Market Size by Country
  8.4.3 Germany Market Overview
  8.4.4 France Market Overview
  8.4.5 U.K. Market Overview
  8.4.6 Italy Market Overview
  8.4.7 Spain Market Overview
8.5 Asia Pacific
  8.5.1 Asia Pacific Flu Vaccine Sales by Region
  8.5.2 Asia Pacific Flu Vaccine Market Size by Region
  8.5.3 China Market Overview
  8.5.4 Japan Market Overview
  8.5.5 South Korea Market Overview
  8.5.6 India Market Overview
  8.5.7 Southeast Asia Market Overview
8.6 South America
  8.6.1 South America Flu Vaccine Sales by Country
  8.6.2 South America Flu Vaccine Market Size by Country
  8.6.3 Brazil Market Overview
  8.6.4 Argentina Market Overview
  8.6.5 Columbia Market Overview
8.7 Middle East and Africa
  8.7.1 Middle East and Africa Flu Vaccine Sales by Region
  8.7.2 Middle East and Africa Flu Vaccine Market Size by Region
  8.7.3 Saudi Arabia Market Overview
  8.7.4 UAE Market Overview
  8.7.5 Egypt Market Overview
  8.7.6 Nigeria Market Overview
  8.7.7 South Africa Market Overview

9 FLU VACCINE MARKET PRODUCTION BY REGION

9.1 Global Production of Flu Vaccine by Region(2020-2025)
9.2 Global Flu Vaccine Revenue Market Share by Region (2020-2025)
9.3 Global Flu Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Flu Vaccine Production
  9.4.1 North America Flu Vaccine Production Growth Rate (2020-2025)
  9.4.2 North America Flu Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Flu Vaccine Production
  9.5.1 Europe Flu Vaccine Production Growth Rate (2020-2025)
  9.5.2 Europe Flu Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Flu Vaccine Production (2020-2025)
  9.6.1 Japan Flu Vaccine Production Growth Rate (2020-2025)
  9.6.2 Japan Flu Vaccine Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Flu Vaccine Production (2020-2025)
  9.7.1 China Flu Vaccine Production Growth Rate (2020-2025)
  9.7.2 China Flu Vaccine Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Sanofi
  10.1.1 Sanofi Basic Information
  10.1.2 Sanofi Flu Vaccine Product Overview
  10.1.3 Sanofi Flu Vaccine Product Market Performance
  10.1.4 Sanofi Business Overview
  10.1.5 Sanofi SWOT Analysis
  10.1.6 Sanofi Recent Developments
10.2 CSL
  10.2.1 CSL Basic Information
  10.2.2 CSL Flu Vaccine Product Overview
  10.2.3 CSL Flu Vaccine Product Market Performance
  10.2.4 CSL Business Overview
  10.2.5 CSL SWOT Analysis
  10.2.6 CSL Recent Developments
10.3 GSK
  10.3.1 GSK Basic Information
  10.3.2 GSK Flu Vaccine Product Overview
  10.3.3 GSK Flu Vaccine Product Market Performance
  10.3.4 GSK Business Overview
  10.3.5 GSK SWOT Analysis
  10.3.6 GSK Recent Developments
10.4 AstraZeneca
  10.4.1 AstraZeneca Basic Information
  10.4.2 AstraZeneca Flu Vaccine Product Overview
  10.4.3 AstraZeneca Flu Vaccine Product Market Performance
  10.4.4 AstraZeneca Business Overview
  10.4.5 AstraZeneca Recent Developments
10.5 Hualan Bio
  10.5.1 Hualan Bio Basic Information
  10.5.2 Hualan Bio Flu Vaccine Product Overview
  10.5.3 Hualan Bio Flu Vaccine Product Market Performance
  10.5.4 Hualan Bio Business Overview
  10.5.5 Hualan Bio Recent Developments
10.6 Changchun Institute of Biological
  10.6.1 Changchun Institute of Biological Basic Information
  10.6.2 Changchun Institute of Biological Flu Vaccine Product Overview
  10.6.3 Changchun Institute of Biological Flu Vaccine Product Market Performance
  10.6.4 Changchun Institute of Biological Business Overview
  10.6.5 Changchun Institute of Biological Recent Developments
10.7 Sinovac
  10.7.1 Sinovac Basic Information
  10.7.2 Sinovac Flu Vaccine Product Overview
  10.7.3 Sinovac Flu Vaccine Product Market Performance
  10.7.4 Sinovac Business Overview
  10.7.5 Sinovac Recent Developments
10.8 BCHT
  10.8.1 BCHT Basic Information
  10.8.2 BCHT Flu Vaccine Product Overview
  10.8.3 BCHT Flu Vaccine Product Market Performance
  10.8.4 BCHT Business Overview
  10.8.5 BCHT Recent Developments
10.9 Jiangsu GDK
  10.9.1 Jiangsu GDK Basic Information
  10.9.2 Jiangsu GDK Flu Vaccine Product Overview
  10.9.3 Jiangsu GDK Flu Vaccine Product Market Performance
  10.9.4 Jiangsu GDK Business Overview
  10.9.5 Jiangsu GDK Recent Developments
10.10 KM Biologics
  10.10.1 KM Biologics Basic Information
  10.10.2 KM Biologics Flu Vaccine Product Overview
  10.10.3 KM Biologics Flu Vaccine Product Market Performance
  10.10.4 KM Biologics Business Overview
  10.10.5 KM Biologics Recent Developments

11 FLU VACCINE MARKET FORECAST BY REGION

11.1 Global Flu Vaccine Market Size Forecast
11.2 Global Flu Vaccine Market Forecast by Region
  11.2.1 North America Market Size Forecast by Country
  11.2.2 Europe Flu Vaccine Market Size Forecast by Country
  11.2.3 Asia Pacific Flu Vaccine Market Size Forecast by Region
  11.2.4 South America Flu Vaccine Market Size Forecast by Country
  11.2.5 Middle East and Africa Forecasted Sales of Flu Vaccine by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)

12.1 Global Flu Vaccine Market Forecast by Type (2026-2035)
  12.1.1 Global Forecasted Sales of Flu Vaccine by Type (2026-2035)
  12.1.2 Global Flu Vaccine Market Size Forecast by Type (2026-2035)
  12.1.3 Global Forecasted Price of Flu Vaccine by Type (2026-2035)
12.2 Global Flu Vaccine Market Forecast by Application (2026-2035)
  12.2.1 Global Flu Vaccine Sales (K MT) Forecast by Application
  12.2.2 Global Flu Vaccine Market Size (M USD) Forecast by Application (2026-2035)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Flu Vaccine Market Size by Type (M USD)
Table 4. Global Flu Vaccine Market Size by Application
Table 5. Flu Vaccine Market Size Comparison by Region (M USD)
Table 6. Global Flu Vaccine Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Flu Vaccine Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Flu Vaccine Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Flu Vaccine Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Flu Vaccine as of 2025)
Table 11. Global Market Flu Vaccine Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers’ Manufacturing Sites, Areas Served
Table 13. Manufacturers’ Product Type
Table 14. Global Flu Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Flu Vaccine Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Flu Vaccine Sales by Type (K MT)
Table 27. Global Flu Vaccine Market Size by Type (M USD)
Table 28. Global Flu Vaccine Sales (K MT) by Type (2020-2025)
Table 29. Global Flu Vaccine Sales Market Share by Type (2020-2025)
Table 30. Global Flu Vaccine Market Size (M USD) by Type (2020-2025)
Table 31. Global Flu Vaccine Market Share by Type (2020-2025)
Table 32. Global Flu Vaccine Price (USD/KG) by Type (2020-2025)
Table 33. Global Flu Vaccine Sales (K MT) by Application
Table 34. Global Flu Vaccine Market Size by Application
Table 35. Global Flu Vaccine Sales by Application (2020-2025) & (K MT)
Table 36. Global Flu Vaccine Sales Market Share by Application (2020-2025)
Table 37. Global Flu Vaccine Market Size by Application (2020-2025) & (M USD)
Table 38. Global Flu Vaccine Market Share by Application (2020-2025)
Table 39. Global Flu Vaccine Sales Growth Rate by Application (2020-2025)
Table 40. Global Flu Vaccine Sales by Region (2020-2025) & (K MT)
Table 41. Global Flu Vaccine Sales Market Share by Region (2020-2025)
Table 42. Global Flu Vaccine Market Size by Region (2020-2025) & (M USD)
Table 43. Global Flu Vaccine Market Size by Region (2020-2025)
Table 44. North America Flu Vaccine Sales by Country (2020-2025) & (K MT)
Table 45. North America Flu Vaccine Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Flu Vaccine Sales by Country (2020-2025) & (K MT)
Table 47. Europe Flu Vaccine Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Flu Vaccine Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Flu Vaccine Market Size by Region (2020-2025) & (M USD)
Table 50. South America Flu Vaccine Sales by Country (2020-2025) & (K MT)
Table 51. South America Flu Vaccine Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Flu Vaccine Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Flu Vaccine Market Size by Region (2020-2025) & (M USD)
Table 54. Global Flu Vaccine Production (K MT) by Region(2020-2025)
Table 55. Global Flu Vaccine Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Flu Vaccine Revenue Market Share by Region (2020-2025)
Table 57. Global Flu Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Flu Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Flu Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Flu Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Flu Vaccine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Sanofi Basic Information
Table 63. Sanofi Flu Vaccine Product Overview
Table 64. Sanofi Flu Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Sanofi Business Overview
Table 66. Sanofi SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. CSL Basic Information
Table 69. CSL Flu Vaccine Product Overview
Table 70. CSL Flu Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. CSL Business Overview
Table 72. CSL SWOT Analysis
Table 73. CSL Recent Developments
Table 74. GSK Basic Information
Table 75. GSK Flu Vaccine Product Overview
Table 76. GSK Flu Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. GSK Business Overview
Table 78. GSK SWOT Analysis
Table 79. GSK Recent Developments
Table 80. AstraZeneca Basic Information
Table 81. AstraZeneca Flu Vaccine Product Overview
Table 82. AstraZeneca Flu Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. AstraZeneca Business Overview
Table 84. AstraZeneca Recent Developments
Table 85. Hualan Bio Basic Information
Table 86. Hualan Bio Flu Vaccine Product Overview
Table 87. Hualan Bio Flu Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Hualan Bio Business Overview
Table 89. Hualan Bio Recent Developments
Table 90. Changchun Institute of Biological Basic Information
Table 91. Changchun Institute of Biological Flu Vaccine Product Overview
Table 92. Changchun Institute of Biological Flu Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Changchun Institute of Biological Business Overview
Table 94. Changchun Institute of Biological Recent Developments
Table 95. Sinovac Basic Information
Table 96. Sinovac Flu Vaccine Product Overview
Table 97. Sinovac Flu Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Sinovac Business Overview
Table 99. Sinovac Recent Developments
Table 100. BCHT Basic Information
Table 101. BCHT Flu Vaccine Product Overview
Table 102. BCHT Flu Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. BCHT Business Overview
Table 104. BCHT Recent Developments
Table 105. Jiangsu GDK Basic Information
Table 106. Jiangsu GDK Flu Vaccine Product Overview
Table 107. Jiangsu GDK Flu Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Jiangsu GDK Business Overview
Table 109. Jiangsu GDK Recent Developments
Table 110. KM Biologics Basic Information
Table 111. KM Biologics Flu Vaccine Product Overview
Table 112. KM Biologics Flu Vaccine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. KM Biologics Business Overview
Table 114. KM Biologics Recent Developments
Table 115. Global Flu Vaccine Sales Forecast by Region (2026-2035) & (K MT)
Table 116. Global Flu Vaccine Market Size Forecast by Region (2026-2035) & (M USD)
Table 117. North America Flu Vaccine Sales Forecast by Country (2026-2035) & (K MT)
Table 118. North America Flu Vaccine Market Size Forecast by Country (2026-2035) & (M USD)
Table 119. Europe Flu Vaccine Sales Forecast by Country (2026-2035) & (K MT)
Table 120. Europe Flu Vaccine Market Size Forecast by Country (2026-2035) & (M USD)
Table 121. Asia Pacific Flu Vaccine Sales Forecast by Region (2026-2035) & (K MT)
Table 122. Asia Pacific Flu Vaccine Market Size Forecast by Region (2026-2035) & (M USD)
Table 123. South America Flu Vaccine Sales Forecast by Country (2026-2035) & (K MT)
Table 124. South America Flu Vaccine Market Size Forecast by Country (2026-2035) & (M USD)
Table 125. Middle East and Africa Flu Vaccine Sales Forecast by Country (2026-2035) & (Units)
Table 126. Middle East and Africa Flu Vaccine Market Size Forecast by Country (2026-2035) & (M USD)
Table 127. Global Flu Vaccine Sales Forecast by Type (2026-2035) & (K MT)
Table 128. Global Flu Vaccine Market Size Forecast by Type (2026-2035) & (M USD)
Table 129. Global Flu Vaccine Price Forecast by Type (2026-2035) & (USD/KG)
Table 130. Global Flu Vaccine Sales (K MT) Forecast by Application (2026-2035)
Table 131. Global Flu Vaccine Market Size Forecast by Application (2026-2035) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Flu Vaccine
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Flu Vaccine Market Size (M USD), 2025-2035
Figure 5. Global Flu Vaccine Market Size (M USD) (2020-2035)
Figure 6. Global Flu Vaccine Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Flu Vaccine Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Flu Vaccine Product Life Cycle
Figure 13. Flu Vaccine Sales Share by Manufacturers in 2025
Figure 14. Global Flu Vaccine Revenue Share by Manufacturers in 2025
Figure 15. Flu Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Flu Vaccine Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Flu Vaccine Revenue in 2025
Figure 18. Industry Chain Map of Flu Vaccine
Figure 19. Global Flu Vaccine Market PEST Analysis
Figure 20. Global Flu Vaccine Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Flu Vaccine Market Share by Type
Figure 27. Sales Market Share of Flu Vaccine by Type (2020-2025)
Figure 28. Sales Market Share of Flu Vaccine by Type in 2025
Figure 29. Market Share of Flu Vaccine by Type (2020-2025)
Figure 30. Market Share of Flu Vaccine by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Flu Vaccine Market Share by Application
Figure 33. Global Flu Vaccine Sales Market Share by Application (2020-2025)
Figure 34. Global Flu Vaccine Sales Market Share by Application in 2025
Figure 35. Global Flu Vaccine Market Share by Application (2020-2025)
Figure 36. Global Flu Vaccine Market Share by Application in 2025
Figure 37. Global Flu Vaccine Sales Growth Rate by Application (2020-2025)
Figure 38. Global Flu Vaccine Sales Market Share by Region (2020-2025)
Figure 39. Global Flu Vaccine Market Size by Region (2020-2025)
Figure 40. North America Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Flu Vaccine Sales Market Share by Country in 2024
Figure 43. North America Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Flu Vaccine Market Size by Country in 2024
Figure 45. U.S. Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Flu Vaccine Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Flu Vaccine Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Flu Vaccine Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Flu Vaccine Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Flu Vaccine Sales Market Share by Country in 2024
Figure 53. Europe Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Flu Vaccine Market Size by Country in 2024
Figure 55. Germany Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Flu Vaccine Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Flu Vaccine Sales Market Share by Region in 2024
Figure 67. Asia Pacific Flu Vaccine Market Size by Region in 2024
Figure 68. China Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Flu Vaccine Sales and Growth Rate (K MT)
Figure 79. South America Flu Vaccine Sales Market Share by Country in 2024
Figure 80. South America Flu Vaccine Market Size and Growth Rate (M USD)
Figure 81. South America Flu Vaccine Market Size by Country in 2024
Figure 82. Brazil Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Flu Vaccine Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Flu Vaccine Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Flu Vaccine Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Flu Vaccine Market Size by Region in 2024
Figure 92. Saudi Arabia Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Flu Vaccine Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Flu Vaccine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Flu Vaccine Production Market Share by Region (2020-2025)
Figure 103. North America Flu Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Flu Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Flu Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 106. China Flu Vaccine Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Flu Vaccine Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Flu Vaccine Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Flu Vaccine Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Flu Vaccine Market Share Forecast by Type (2026-2035)
Figure 111. Global Flu Vaccine Sales Forecast by Application (2026-2035)
Figure 112. Global Flu Vaccine Market Share Forecast by Application (2026-2035)